17.18

3.79% -0.6675

Monte Rosa Therapeutics Inc (GLUE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GLUE? Forum Prognose

Schlusskurs vom Vortag:

$17.85

Offen:

$17.69

24-Stunden-Volumen:

362.80K

Relative Volume:

0.24

Marktkapitalisierung:

$1.12B

Einnahmen:

Nettoeinkommen (Verlust:

$-130.41M

KGV:

-7.6708

EPS:

-2.24

Netto-Cashflow:

$-67.76M

1W Leistung:

+11.44%

1M Leistung:

+39.51%

6M Leistung:

+249.05%

1J Leistung:

+68.37%

1-Tages-Spanne:

$17.12

$18.05

1-Wochen-Bereich:

$15.21

$18.15

52-Wochen-Spanne:

$3.5001

$18.15

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Firmenname

Monte Rosa Therapeutics Inc

Sektor

Healthcare (1139)

Branche

Biotechnology (634)

Telefon

617-949-2643

Adresse

321 HARRISON AVENUE, BOSTON

Mitarbeiter

147

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

GLUE's Discussions on Twitter

Vergleichen Sie GLUE mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GLUE Monte Rosa Therapeutics Inc	17.18	1.16B	0	-130.41M	-67.76M	-2.24
VRTX Vertex Pharmaceuticals Inc	438.40	112.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	699.97	73.91B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	417.88	56.81B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	892.65	55.46B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	193.75	41.92B	447.02M	-1.18B	-906.14M	-6.1812

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-19	Herabstufung	Wells Fargo	Overweight → Equal Weight
2024-02-15	Eingeleitet	Wedbush	Outperform
2023-01-03	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-10-13	Eingeleitet	UBS	Buy
2022-08-15	Eingeleitet	Jefferies	Buy
2022-04-28	Eingeleitet	Credit Suisse	Neutral
2022-02-10	Eingeleitet	Wells Fargo	Equal Weight
2021-10-14	Eingeleitet	SVB Leerink	Mkt Perform

Alle ansehen

Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten

05:09 AM

Monte Rosa Therapeutics (NASDAQ:GLUE) Sets New 52-Week HighStill a Buy? - MarketBeat

05:09 AM

03:00 AM

Monte Rosa Therapeutics (NASDAQ:GLUE) Nasdaq Futures Biotech Momentum - Kalkine Media

03:00 AM

Dec 06, 2025

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - sharewise.com

Dec 06, 2025

Dec 03, 2025

Monte Rosa Therapeutics stock hits 52-week high at $16.66 By Investing.com - Investing.com India

Dec 03, 2025

Monte Rosa Therapeutics stock hits 52-week high at $16.66 - Investing.com

Dec 03, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st

Dec 03, 2025

Dec 02, 2025

Monte Rosa Therapeutics (GLUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 02, 2025

Dec 01, 2025

Improved Revenues Required Before Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock's 26% Jump Looks Justified - 富途牛牛

Dec 01, 2025

Nov 30, 2025

Monte Rosa: Looking Mispriced After Big Pharma Validation (NASDAQ:GLUE) - Seeking Alpha

Nov 30, 2025

Nov 28, 2025

How Monte Rosa Therapeutics Inc. stock reacts to inflationary pressuresQuarterly Earnings Summary & Real-Time Buy Signal Notifications - moha.gov.vn

Nov 28, 2025

Nov 27, 2025

Monte Rosa Therapeutics Jumps 124.9% in 2025 But Are Investors Getting Ahead of Themselves - Yahoo Finance

Nov 27, 2025

Nov 26, 2025

Hillsdale Investment Management Inc. Makes New $271,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat

Nov 26, 2025

Nov 25, 2025

Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat

Nov 25, 2025

Nov 23, 2025